News

NICE asks for further information to make a final decision on use of idelalisib with rituximab to treat adults with chronic lymphocytic leukaemia

18 June 2015

NICE has asked for further information from the company to make a final decision on the use of idelalisib in combination with the drug rituximab for adults with chronic lymphocytic leukaemia whose disease is refactory to other treatments when it is not considered appropriate to treat again with previous therapies.

NICE publishes guidance for NHS England & Wales use of obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia

Technology appraisal guidance [TA343] Published today June 2015

You can access full guidance details on the NICE website here:http://www.nice.org.uk/guidance/ta343

Obinutuzumab (Gazyvaro), given with a drug called chlorambucil, is recommended as a possible treatment for adults with untreated chronic lymphocytic leukaemia only if:

NICE publishes guidance for NHS England & Wales use of ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia

Technology appraisal guidance [TA344] Published today June 2015
You can access full guidance details on the NICE website here:http://www.nice.org.uk/guidance/ta344

Ofatumumab (Arzerra) given with a drug called chlorambucil is recommended as a possible treatment for people with untreated chronic lymphocytic leukaemia if treatments containing fludarabine or bendamustine are not suitable.

What does this mean for me?

CLLSA runner and fundraiser Laurie completes The Belfast Marathon inside target time.

CLLSA member Laurie has been part of Molly's team and has run in the London 10k to raise funds for CLLSA for the past two years. Unfortunately Laurie is unable to make the London run this year but has just taken on the Belfast Marathon instead to raise funds to support the CLLSA.

Laurie completed the run on Monday 4th May in a time of 3:29:17. Laurie was aiming for about 3:30 so was very happy with the finishing time. 

Vitality British 10k London Run – CLLSA Fundraising

For the third consecutive year runners are entering the British 10k London Run on behalf of the CLL Support Association (CLLSA).  It is being held on the 12th July 2015 and below you can see some information taken from their website which explains a little about the race:

“The British 10k London Run is staged on the world’s greatest road race route through the heart of Central London passing many of the Capitals truly world class historic landmarks”

A Wales & West CLLSA members meeting will be held in Bristol on Monday 28th September 2015

Wales & West CLLSA members meeting - Bristol - Monday September 28th 2015

The event is now confirmed and  in set up, a venue has been reserved and details will be released very soon to enable you to consider detailed planning and reservations. In the meantime please add it to your diaries for planning purposes.

Keynote talks will be provided by  University of Wales clinical and research experts Professor Chris Fegan & Professor Chris Pepper .

There is no cost to attend and a complimentary lunch and refreshments will be provided.

Idelalisib gains SMC approval for NHS Scotland use + early access programme

Idelalisib (Zydelig) has been accepted for restricted use by NHS Scotland. you can read more & access the full guidance PDF from the download on the SMC website.  

CLLSA have participated in the consultation process,  it is rewarding to see this now gain approval.  

SMC intitial guidance details:

following a full submission